top of page

Michael J. Soileau, MD

Dr. Michael Soileau grew up in Lumberton, TX (small town in Southeast Texas) prior to his moving to Waco, TX for college at Baylor University.  After graduating from Baylor University, he attended medical school at The University of Texas Medical School in Houston after which he moved to Ann Arbor, Michigan where he completed his neurology residency at the prestigious University of Michigan.  While in Ann Arbor, he was honored with numerous teaching awards and fell in love with the field of Movement Disorders.  Rarely in neurology, can there be such an influential and immediate improvement in quality of life.  This love prompted him to return to his medical school alma mater and complete a fellowship in the medical and surgical management of movement disorders. 

​

After directing the movement disorder division at a large institution in Central Texas for 3 years and starting a DBS program, he decided to open Texas Movement Disorder Specialists, PLLC in 2017.  Doing so allowed him to bring “big city training” to smaller towns as a convenience to his patients.  Now, he continues to provide comprehensive, sub-specialized care to those patients with movement disorders in a compassionate, individualized manner.  He continues to develop a regional and statewide presence having patients travel from all over Texas, Oklahoma, and New Mexico.  

 

Dr. Soileau also enjoys teaching students, residents, and other neurologists about the “art” of treating movement disorders as well as advanced therapies.  In his short tenure to date, he’s traveled regionally and nationally as a consultant and lecturer to patients and providers, authored several book chapters, peer-reviewed journal articles, and co-authored a board review textbook for neurology students and providers.  He is also a member of the prestigious Parkinson Study Group (PSG) as well as a board member of the Texas Neurological Society.  

 

When not at work, he enjoys spending quality time with his wife Janiece (a pediatric nurse practitioner), his 3 sons, and his golden retriever Dixie.

​

 

 

 

 

 

 

 

 

 

​

​​

​

20200830_080701.jpg
IMG_2765_DxO.jpg
20230517_115847.jpg

Honors and Awards

  • 2022 Awarded Fellow, American Academy of Neurology

  • 2019 American Academy of Neurology (AAN) Practice Leadership Program – 1 of 9 chosen in US (United States) 

  • 2015 Capital Area Parkinson's Society — honored for presentation, support, and commitment

  • 2013 Status Pedagogicus in Situ Award.”  (Given to resident recognizing teaching and mentorship excellence.)

  • 2010, 2011, 2012, 2013 “Making a Difference”, University of Michigan. (Patient or staff nominated award for excellent clinical care.)

  • 2010 Recipient of the “Bronze Beeper Award for Teaching”

  • 2009 Truman G. Blocker, JR Gold-Headed Cane Award for Humanism in Medicine

​

Published – Peer Reviewed

  1. Soileau, M.J., Pagan, F.L., Fasano, A. et al. Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease. Neurol Ther (2023). https://doi.org/10.1007/s40120-022-00433-w

  2. Soileau, M.J et al. Safety and Efficacy of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: A Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. Lancet Neurology (2022) Volume 21, Issue 12 P1099-1109, Dec 01, 2022

  3. Soileau MJ, Pagan F, Fasano A, Rodriguez-Cruz R, Wang L, Kandukuri PL, Yan CH, Alobaidi A, Bao Y, Kukreja P, Oh M, Siddiqui MS. Comparative Effectiveness of Carbidopa-Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson's Disease-Related Pill Burden Reduction in Advanced Parkinson's Disease: A Retrospective Real-World Cohort Study. Neurol Ther. 2022 Jun;11(2):851-861. doi: 10.1007/s40120-022-00351-x. Epub 2022 Apr 20. PMID: 35441973; PMCID: PMC9095798.

  4. Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, Soileau MJ, et al. Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. 2022 Jan 24;22(1):35. doi: 10.1186/s12883-022-02560-1. PMID: 35073872.

  5. Antonini, A., Pahwa, R., Odin, P. Soileau, MJ et al. Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence from G7 Countries. Neurol Ther (2022)

  6. Bluett, B., Togasaki, D. M., Mihaila, D., Evatt, M., Rezak, M., Jain, S., ... Soileau, MJ & Parkinson Study Group SURE-PD3 Investigators. (2021). Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA, 326(10), 926-939. 

  7. Thakkar, S., Fung, V. S., Merola, A., Rollins, M., Soileau, M. J., & Kovács, N. (2021). 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations. CNS drugs, 1-13. 

  8. Isaacson, S. H., Peckham, E., Tse, W., Waln, O., Way, C., Petrossian, M. T., Soileau, MJ ... & Pahwa, R. (2020). Prospective home-use study on non-invasive neuromodulation therapy for essential tremor. Tremor and Other Hyperkinetic Movements, 10. 

  9. Benge, J. F., Balsis, S., Madeka, T., Uhlman, C., Lantrip, C., & Soileau, M. J. (2017). Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease. Parkinsonism & related disorders, 41, 104-108. 

  10. Cooper, R. A., Benge, J., Lantrip, C., & Soileau, M. J. (2017, July). The Everyday Cognition scale in Parkinson's disease. In Baylor University Medical Center Proceedings (Vol. 30, No. 3, pp. 265-267). Taylor & Francis. 

  11. Montgomery, M. L., Miner, N. K., Soileau, M. J., & McDonald, D. K. (2016, October). Placement of the AbbVie PEG-J tube for the treatment of Parkinson's disease in the interventional radiology suite. In Baylor University Medical Center Proceedings (Vol. 29, No. 4, pp. 420-422). Taylor & Francis. 

  12. Soileau, M. J., Persad, C., Taylor, J., Patil, P. G., & Chou, K. L. (2014). Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: an exploratory analysis. Journal of Parkinson's disease, 4(3), 517-521.

  13. Hallevi, H., Chernyshev, O. Y., El Khoury, R., Soileau, M. J., Walker, K. C., Grotta, J. C., & Savitz, S. I. (2012). Intracranial atherosclerosis is associated with progression of neurological deficit in subcortical stroke. Cerebrovascular Diseases, 33(1), 64-68.

 

Published – Non-Peer Reviewed

  1. Soileau M.J. and Furr-Stimming, E. "Inpatient Management of Parkinson's Disease." Practical Neurology. October 2014, Vol 13, No. 8.

 

Book Chapters

  1. Michael J. Soileau.  Defining Idiopathic Parkinson Disease.  In Armitage, AE (2017) Fast Facts for Nurses about Parkinson’s Disease: An Expert Guide in a Nutshell, 1e.  Springer Publishing.  

  2. Michael J. Soileau. Imaging and Advanced Studies.  In Armitage, AE (2017) Fast Facts for Nurses about Parkinson’s Disease: An Expert Guide in a Nutshell, 1e.  Springer Publishing.  

  3. Michael J. Soileau and Kelvin L. Chou. Parkinson Disease: Pathophysiology, Genetics, Clinical Manifestations and Course including Diagnosis and Differential Diagnosis. In: Johnston et al (ed) (2016) Neurobiology of Disease, 2e. Oxford University Press

  4. Soileau, Michael J and Kelvin L. Chou. Common Challenges and Complications in the Inpatient Setting. In: Hawley, Armstrong, Weiner (eds). (2014) Parkinson's Disease: Improving Patient Care, pp. 75-87, Oxford University Press

 

Book Publications (Author)

  1. Jordan, J. T., Mayans, D. R., & Soileau, MJ. (2016). Neurology Self-Assessment: A

Companion to Bradley's Neurology in Clinical Practice, 224 pp., Elsevier Health Science.

 

Abstracts

  1. Aldred, J, Soileau, MJ et al (2023).  Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson's disease.  Poster at International Parkinson and Movement Disorder Society Congress: 2023.

  2. Aldred, J, Soileau, MJ et al (2023).  Foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease: subgroup analyses from a phase 3, randomized study.  Poster at International Parkinson and Movement Disorder Society Congress: 2023.

  3. Aldred, J, Soileau, MJ et al (2023).  Challenges with oral anti-parkinsonian medications and opportunities with continuous subcutaneous infusion (CSCI) of Foslevodopa/Foscarbidopa (LDP/CDP) for treatment of Advanced Parkinson’s Disease (aPD).  Poster at International Parkinson and Movement Disorder Society Congress: 2023.

  4. Pahwa, R, Soileau, MJ et al (2023).  Stability and predictability of motor symptom control in patients with advanced Parkinson’s disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP).  Poster at International Parkinson and Movement Disorder Society Congress: 2023.

  5. Pahwa, R, Soileau, MJ et al. (2023). Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa. Poster at IAPRD 2023

  6. Kukreja, P, Soileau MJ. (2023) Summative human factors validation of the foslevodopa/foscarbidopa (ABBV-951) continuous subcutaneous infusion drug delivery system by Parkinson’s disease patients, caregivers, and healthcare professionals. Poster at World Parkinson Congress 2023

  7. Fernandez, Hubert, Soileau MJ et al. (2023) Geographic Disparities and Access to Device-Aided Therapy Services for Medicare Beneficiaries with Advanced Parkinson's Disease. Poster at IAPRD 2023

  8. Kumar, R, Soileau MJ et al. (2023) Patient Experience and Treatment Satisfaction with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease. Poster at World Parkinson's Congress (WPC) 2023

  9. Gibbons, Christopher, Soileau MJ et al. (2023) The Synuclein-One Study: Skin Biopsy Detection of Phosphorylated alpha-synuclein for Diagnosis of the Synucleinopathies. Poster at American Academy of Neurology (AAN) Conference: 2023

  10. Soileau M et al. (2022). Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa. Poster at International Parkinson and Movement Disorder Society Congress: 2022.

  11. Soileau M et al. (2022) Subcutaneous Foslevodopa/Foscarbidopa in Patients with Advanced Parkinson’s Disease: Results from a Randomized, Double-blind, Double-dummy Phase 3 Trial. Poster at International Parkinson and Movement Disorder Society Congress: 2022. 

  12. Soileau M et al. (2022) Impact of Foslevodopa/Foscarbidopa on Key Clinical and Patient-Reported Outcomes in Patients with aPD: Responder Analysis of Two Phase 3 Clinical Trials. Poster at International Parkinson and Movement Disorder Society Congress: 2022. 

  13. Soileau M et al. (2021) Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients with Advanced Parkinson’s Disease. Poster at International Parkinson and Movement Disorder Society Congress: 2021. 

  14. Gupta, N, Soileau, MJ et al (2021). Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension. Poster at International Parkinson and Movement Disorder Society Congress: 2021. 

  15. Pagan, F., Rodriguez-Cruz, R., Soileau, M., Alobaidi, A., Kandukuri, P., Hayes, O., ... & Siddiqui, M. (2021). Real-world characteristics and treatment persistence in patients initiating CLES: Results from a cohort of 1290 patients in USA (2429). Poster at AAN 2021.

  16. Siddiqui, M, Soileau, MJ et al (2021). Sustained Pill Burden Reduction among Medicare Fee-For-Service Patients with Advanced Parkinson's Disease after Initiation of Carbidopa/Levodopa Enteral Suspension (CLES). Poster At International Association Parkinsonism and Related Disorders (IAPRD): 2021

  17. Antonini, A., Odin, P., Henriksen, T., Soileau, M., Rodriguez-Cruz, R., Alobaidi, A., ... & Chaudhuri, K. (2020). Does “5-2-1” identify patients with suspected Advanced Parkinson's Disease? Evidence of clinical accuracy from G7 countries: 1165. Movement Disorders, 35. Poster at International Parkinson and Movement Disorder Society Congress: 2020.

  18. Soileau, M., Pagan, F., Fasano, A., Rodriguez-Cruz, R., Oh, M., Kandukuri, P., ... & Siddiqui, M. (2020). Pill burden reduction in patients with advanced Parkinson's disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation: 1065. Movement Disorders, 35.  Poster at International Parkinson and Movement Disorder Society Congress: 2020.

  19. Pahwa, R., Peckham, E., Tse, W., Waln, O., Way, C., Petrossian, M., Soileau MJ ..., & Isaacson, S. (2020). Symptomatic Relief in Essential Tremor with Home Use of Non-Invasive Neuromodulation Therapy (435). Poster at American Academy of Neurology (AAN) Toronto: 2020. 

  20. Ospina, M. C., Soileau, M. J., Brillman, S., Reed, C., Shah, P., & Jones, S. (2020). Impact of Levodopa/Carbidopa Intestinal Gel Delivery on CarePartner Burden and Quality of Life: Survey by Parkinson & Movement disorder alliance. Parkinsonism & Related Disorders, 79, e89-e90. 

  21. Benge, J., Pineda, A., Balsis, S., & Soileau, M. (2016). C-69 Caregiver Perceptions of Everyday Cognitive Functioning in Parkinson's Disease. Archives of Clinical Neuropsychology, 31(6). Poster presented at the annual meeting of the National Academy of Neuropsychology, Seattle, WA. 

  22. Chernyshev, O. Y., El Khoury, R., Soileau, MJ., Walker, K. C., Grotta, J. C., Savitz, S. I., & Hallevi, H. (2009, April). Intracranial Atherosclerosis Predicts Neurological Fluctuations in Subcortical Ischemic Stroke. In STROKE (Vol. 40, No. 4, pp. E243-E243).

  23. Chernyshev OY, Martin-Schild S, El Khoury R, Soileau MJ, Lentz RJ, Morales MM, Sline MR, Grotta JC, Savitz SI. (2009) Delay in Hospital Arrival in Patients with Posterior Circulation Ischemia. Stroke. 2009; 40: e105-e276.

 

Poster Presentations

  1. Caregiver Burden in Patients with Parkinson Disease Undergoing Deep Brain

Stimulation. University of Michigan Neuroscience Day 2012, Ann Arbor, Michigan.

  1. Delay in Hospital Arrival in Patients with Posterior Circulation Ischemia. — Poster presentation at the International Stroke Conference, San Diego, California 2009

 

Online Courses                                            

  1. “Huntington’s Disease: Motor Symptoms and Treatment” – International Parkinson and Movement Disorder Society.  https://www.movementdisorders.org/MDS/Education/Latest-E-Learning.htm.  June 2018

 

Research - Clinical Trials

  • 2023: Jazz Pharmaceuticals.  “A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkinson’s Disease”.  Michael Soileau, MD (Site PI)

  • 2023: Scion Neurostim “Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial (RCT)” Michael Soileau, MD (Site PI)

  • 2022: Abbvie Protocol M21-471: “A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor” Michael Soileau, MD (Site PI)

  • 2022: Abbott Neuromodulation, ADROIT Study “Abbott DBS Post-Market Study of Outcomes for Indications Over Time” Michael Soileau, MD (Site PI)

  • 2022: Abbott Neuromodulation, ROAM Study “Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation.” Michael Soileau, MD (Site PI)

  • 2021: Praxis Precision Medicines Prax-944: “A Clinical Trial of 3 Doses of PRAX-944 in Participants with Essential Tremor.” Michael Soileau, MD (Site PI)

  • 2021: Teva Protocol TV50717-CNS-40189: “Real-World Utilization of Deutetrabenazine Initiated by a 4-week Patient Titration Kit.”  Michael Soileau, MD (Site PI)

  • 2021: Abbvie Protocol M20-339: “Parkinson's Disease: A Comparative Study of the Levodopa and Carbidopa Bioavailability Following Foslevodopa/foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients.”  Michael Soileau, MD (Site PI)

  • 2021: NIH SBIR R44 NS117214, CND Life Sciences – Todd Levine, MD (Sponsor-Investigator). “Synuclein-One Study: Cutaneous Phosphorylated α-synuclein Detection as a Biomarker of Synucleinopathy”  Michael Soileau, MD (Site PI)

  • 2021: Abbvie Protocol H20-012: “A Prospective Observational Study to Evaluate the Clinical Outcomes and Burden of Disease of PD Patients with Motor Fluctuations Not Adequately Controlled by Current PD Medications.”  Michael Soileau, MD (Site Sub-Investigator)

  • 2020: Cerevel Therapeutics, LLC Protocol No. CVL-751-PD-004: “58 Week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial).”   Michael Soileau, MD (Site PI)

  • 2020: Cerevel Therapeutics, LLC Protocol No. CVL-751-PD-003: “A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible Dose, 27 Week Trial to evaluate the Efficacy, Safety, and Tolerability of Tavapadon as adjunctive therapy for Parkinson’s Disease in Levodopa-treated adults with motor fluctuations (TemPo-3 Trial).”  Michael Soileau, MD (Site PI)

  • 2020: Cerevel Therapeutics, LLC Protocol No. CVL-751-PD-001: “A phase 3, double-blind, randomized, placebo controlled, parallel group, 27-week trial to evaluate the efficacy, safety, and tolerability of two fixed doses of Tavapadon in early Parkinson’s disease (Tempo-1 trial).”   Michael Soileau, MD (Site PI)

  • 2020: AbbVie Protocol No. M20-098 “An Open-Label Extension of Study M15-736 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson's Disease”. Michael Soileau, MD (Site PI)

  • 2020: AbbVie Protocol No. M15-736 “A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients.”  Michael Soileau, MD (Site PI)

  • 2019: AbbVie Protocol No. M15-741 “A 52-Week, open-label single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson’s disease.”  11/2019 to 12/2019, Michael Soileau, MD (Site PI). 

  • 2018: Prospective study for symptomatic relief of Essential Tremor with CALA therapy (PROSPECT). Michael Soileau MD (Site PI) 

  • 2016-2017: NINDS NIH #100,896, Protocol #: INO-PD-P3-2014; 05/2016-05/2020, Michael Soileau, MD (Site PI), Richard Lenehan, MD (Site Co-PI), Michael A. Schwarzschild, MD (Sponsor-Investigator) A Randomized, Double-Blind, Placebo-Controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline and Early Parkinson's Disease (SURE-PD3), $5,170,824 ($216,399) 

bottom of page